September 2024
Aligos Therapeutics’ HERALD Study Shows Promising MASH Treatment Results, Yet Fails to Impress Investors
Aligos Therapeutics, HERALD study, MASH treatment, ALG-055009, liver fat reduction, Phase 2a results, investor reaction.
Basilea Secures $268M BARDA Funding for Antifungal and Antibacterial Development
Basilea, BARDA, antifungals, antibacterials, biotech funding, pharmaceutical development
GC Therapeutics Secures $75 Million Funding for Revolutionary Stem Cell Technology
GC Therapeutics, George Church, stem cell startup, biotech funding, transcription factor screening
FDA Cancels Advisory Committee Meeting for Applied Therapeutics’ Govorestat, Stock Surges 65%
Applied Therapeutics, FDA, Advisory Committee, Govorestat, Galactosemia, Stock Surge
Theratechnologies Warns of Temporary Supply Disruption for EGRIFTA SV in Early 2025 Due to Third-Party Facility Shutdown
Theratechnologies, EGRIFTA SV, supply disruption, third-party facility shutdown, HIV drug, 2025
Upstream Biotech Prepares to Join the Wave of Biotech IPOs with Inflammation-Focused Therapies
Biotech IPOs, Upstream Biotech, Inflammation-focused therapies, Biotechnology industry, Public offerings, Healthcare innovation
GSK Advances Co-Administration of RSV and Shingles Vaccines with Positive Phase III Data
GSK, RSV vaccine, Shingles vaccine, Arexvy, Shingrix, co-administration, Phase III data, adult immunization
Summit’s Ivonescimab Shows Promising Results Over Keytruda in NSCLC, But Global Validation Needed
NSCLC, Ivonescimab, Keytruda, Bispecific Antibody, Lung Cancer Treatment
AstraZeneca Secures FDA Approval for Fasenra in Rare Autoimmune Disorder EGPA
AstraZeneca, Fasenra, FDA approval, EGPA, rare autoimmune disorder, asthma biologic
Enhanced Manufacturing Efforts by Sanofi and AstraZeneca Aim to Prevent Beyfortus Shortfalls in 2024
Beyfortus, RSV prevention, monoclonal antibody, Sanofi, AstraZeneca, manufacturing efforts, supply chain management